Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical Inc.    BMRN

Delayed Quote. Delayed  - 05/03 09:59:58 pm
85.09 USD   -2.08%
05/03 BIOMARIN PHARMA : Announces EMA Grants Accelerated Assessment for Ce..
05/03 BioMarin Announces EMA Grants Accelerated Assessment for Cerlipo..
04/28 BIOMARIN PHARMA : reports 1Q loss
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/27/2016 04/28/2016 04/29/2016 05/02/2016 05/03/2016 Date
87.72(c) 85.1(c) 84.68(c) 86.9(c) 85.09(c) Last
1 011 259 1 476 841 1 705 844 1 112 505 1 012 384 Volume
-1.12% -2.99% -0.49% +2.62% -2.08% Change
More quotes
Financials ($)
Sales 2016 1 091 M
EBIT 2016 -343 M
Net income 2016 -369 M
Debt 2016 311 M
Yield 2016 -
Sales 2017 1 336 M
EBIT 2017 -185 M
Net income 2017 -243 M
Debt 2017 431 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 12,9x
EV / Sales 2017 10,7x
Capitalization 13 812 M
More Financials
Company
BioMarin Pharmaceutical, Inc. engages in the development and commercialization of innovative pharmaceuticals for serious diseases and medical conditions.It operates its business through one segment, the biopharmaceutical development and commercialization segment.Its company's products include... 
Sector
Pharmaceuticals
Calendar
06/06Shareholder meeting
More about the company
Surperformance© ratings of BioMarin Pharmaceutical In
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL IN
05/03 BIOMARIN PHARMACEUTICAL : Announces EMA Grants Accelerated Assessment for Cerlip..
05/03 BioMarin Announces EMA Grants Accelerated Assessment for Cerliponase Alfa, E..
04/28 BIOMARIN PHARMACEUTICAL : reports 1Q loss
04/28 BIOMARIN PHARMACEUTICAL INC : Results of Operations and Financial Condition, Fin..
04/28 BioMarin Announces First Quarter 2016 Financial Results
04/25BIOMARIN PHARMACEUTICAL INC. : quaterly earnings release
04/22 BIOMARIN PHARMACEUTICAL : Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusi..
04/21 BioMarin Enrolls First Patient in Phase 1/2 Trial of NAGLU Fusion Protein BMN..
More news
Sector news : Generic Pharmaceuticals
09:03a MERCK AT SID : Materials for the Displays of Today and Tomorrow
08:50aDJJ&J Appeals $127 Million in Awards in Talc Cancer Cases -- WSJ
08:46a ASTRAZENECA : *hsbc cuts astrazeneca price target to 4240 pence - 'hold'
More sector news : Generic Pharmaceuticals
News from SeekingAlpha
04/28 BioMarin Pharmaceutical (BMRN) Jean-Jacques Bienaimé on Q1 2016 Results - Ear..
04/28 BioMarin Pharmaceutical beats by $0.26, misses on revenue
04/27 Notable earnings after Thursday?s close
04/26 Summit moving ahead with DMD candidate, mid-stage study sites expand to the U..
04/26 Is Sarepta Likely To Gain Approval After Advisory Committee Results?


Comments 
Advertisement
Chart BIOMARIN PHARMACEUTICAL IN
Duration : Period :
BioMarin Pharmaceutical In Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Full-screen chart
Technical analysis trends BIOMARIN PHARMACE...
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions